<DOC>
	<DOCNO>NCT00784082</DOCNO>
	<brief_summary>In sickle cell disease ( SCD ) , polymerisation haemoglobin S result shape change red blood cell ( RBC ) lead vascular occlusion severe painful crisis . Permanent inflammatory state abnormal RBC adhesion endothelium trigger phenomenon . Hydroxyurea ( HU ) drug show reduce clinical severity SCD , initially attribute stimulation foetal haemoglobin ( HbF ) . However , clinical response correlate consistently degree time HbF increment , suggest HU clinical benefit may involve mechanism induction natural anti-inflammatory response via hypothalami-pituitary-adrenal axis .</brief_summary>
	<brief_title>Inflammatory Response Hydroxyurea Therapy Sickle Cell Disease</brief_title>
	<detailed_description>Plasmatic proinflammatory molecule ( C-reactive protein , orosomucoid , RANTES , IL-6 , IL-8 , MCP-1 , IL-1A , IL-1B , ET-1 , IL-4 , IL-10 , TNFalpha , IFNgamma ) , hormones hypothalami-pituitary-adrenal axis ( cortisol , ACTH ) , hypothalamic peptids ( arginine vasopressin , corticotrophin-releasing hormone ) measure SCD child treat HU ( 20 treat child , 20 untreated child history vaso-occlusive event , 20 asymptomatic child , 20 healthy African control ) .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Homozygous SS sickle cell child , age &gt; 3 year , subSaharian Africa extraction , steadystate disease ( free infectious vasoocclusive event 4 week prior 2 week blood sampling , transfusionfree 4 month prior blood sample ) , take drug except penicillinV , folate iron supplementation , hydroxyurea , divide three group : child treat hydroxyurea 2025 mg/kg/day since least 3 month clinical efficacy vasoocclusive event untreated child major vasoocclusive event child &gt; 5 yearold without history vasoocclusive event Signed informed consent obtain subject ( possible ) parent 2 . Controls : heterozygous AS parent sibling patient , AA siblings healthy African unrelated subject , age &gt; 3 year , take drug day blood sample . Signed informed consent obtain subject ( possible ) parent EXCLUSION CRITERIA : Children acutephase disease Parent 's patient 's refusal Taking drug except penicillinV , folate iron supplementation , hydroxyurea Unhealthy control take drug</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Sickle cell disease , hydroxyurea , inflammation</keyword>
</DOC>